



## Erratum

# Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”



Maira da Costa Cacemiro<sup>a,\*</sup>, Juçara Gastaldi Cominal<sup>a</sup>, Raquel Tognon<sup>b</sup>,  
Natalia de Souza Nunes<sup>a</sup>, Belinda Pinto Simões<sup>c</sup>, Lorena Lôbo de Figueiredo-Pontes<sup>c</sup>,  
Luiz Fernando Bazzo Catto<sup>c</sup>, Fabíola Traina<sup>c</sup>, Elizabeth Xisto Souto<sup>d</sup>,  
Fabiana Albani Zambuzi<sup>a</sup>, Fabiani Gai Frantz<sup>a</sup>, Fabíola Attié de Castro<sup>a</sup>

<sup>a</sup> Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo (FCFRP-USP), Ribeirão Preto, SP, Brazil

<sup>b</sup> Universidade Federal de Juiz de Fora (UFJF), Governador Valadares, MG, Brazil

<sup>c</sup> Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRPUSP), Ribeirão Preto, SP, Brazil

<sup>d</sup> Hospital Estadual de Transplantes Euryclides de Jesus Zerbini, São Paulo, SP, Brazil

In the article “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”, published in *Hematol Transfus Cell Ther.* 2018;40(2):120–131, DOI of original article: <https://doi.org/10.1016/j.htct.2017.12.003>, in the Methods section (Blood samples), where it reads:

“11 ET patients, 16 PMF patients, and 20 PV patients”,

It should read:

“12 ET patients, 17 PMF patients, and 23 PV patients”

In Table 1, ET column, where it reads:

5, it should read 6 (Male line) and where it reads 4, it should read 6 (Female line).

In Figure 1 legend, where it reads:

“essential thrombocythemia (ET; n = 11), primary myelofibrosis (PMF; n = 16), and polycythemia vera (PV; n = 20).”,

It should read:

“essential thrombocythemia (ET; n = 12), primary myelofibrosis (PMF; n = 17), and polycythemia vera (PV; n = 23).”

In Figure 2 legend, where it reads:

“MF patients (n = 11)”,

It should read:

“MF patients (n = 12)”

In Figure 5 legend, where it reads:

“myelofibrosis patients (n = 16)”,

It should read:

“myelofibrosis patients (n = 15)”

DOI of original article: <https://doi.org/10.1016/j.htct.2017.12.003>.

\* Corresponding author at: Laboratório de Hematologia, Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo – USP, Av. do Café, s/n°. Campus Universitário, Ribeirão Preto, SP 14040-903, Brazil.

E-mail address: [mairacacemiro@hotmail.com](mailto:mairacacemiro@hotmail.com) (M.C. Cacemiro).

<https://doi.org/10.1016/j.htct.2020.11.001>

2531-1379/© 2018 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).